Canada Institutes New ASF Vaccine Research

03:28PM Jan 16, 2020
autogenous vaccine 08
This month, the VIDO-InterVac facility will begin work with the virus in its Containment Level 3-Agriculture facility in Saskatoon. It is the first non-government facility to work with the virus in Canada.
( Newport Labs )

The Canadian Food Inspection Agency (CFIA) has announced that the University of Saskatchewan’s Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) will work with African swine fever (ASF) to support Canada’s preparedness strategy by increasing its research capacity, according to a release from CFIA.

This collaboration is aimed at developing and testing vaccines and antivirals for ASF. The disease has not been introduced in Canada as of yet, the release notes. This month, the VIDO-InterVac facility will begin work with the virus in its Containment Level 3-Agriculture (CL3-Ag) facility in Saskatoon. It is the first non-government facility to work with the virus in Canada.

"CFIA's support increases Canada's international contribution to combat the spread of ASF. This is a prime example of how this CL3-Ag infrastructure supports national priorities against emerging infectious disease and the development of solutions that mitigate their impact,” says Dr. Volker Gerdts, director, VIDO-InterVac.

The facility had previously developed new vaccines for animal diseases, including porcine epidemic diarrhea virus and contagious bovine pleuropneumonia.